Citation: Lang T, Siribaddana S (2012) Clinical Trials Have Gone Global: Is This a Good Thing? PLoS Med 9(6): e1001228. https://doi.org/10.1371/journal.pmed.1001228
Published: June 12, 2012
Copyright: © 2012 Lang and Siribaddana. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: No specific funding was received for writing this article.
Competing interests: SS has been funded by the Wellcome Trust UK and had several travel grants from Servier (before 1999), Novo Nordisk (before 1999), and Elly Lilly (before 1999). SS is also ethics review committee chairman of the Faculty of Medicine and Allied Sciences Rajarata University of Sri Lanka. TAL has declared that no competing interests exist.
Provenance: Commissioned; externally peer reviewed.
- Clinical trials are conducted across the globe for perfectly good reasons. This is positive because populations in developing countries are under-represented in research.
- Research sites in developing countries benefit from working with externally sponsored clinical trials because they benefit from increased capacity development and investment.
- Locally led research is becoming harder to undertake in developing countries because of complex trial regulations and administrative burdens. There should be a balance between local and externally led trials.
- There is a need for more trials that compare different approaches to managing disease and health issues. This is especially true in low-income settings where simple interventions could make significant improvements to health outcomes if there was evidence to support implementation.
- Clinical trials operations should be specific to the risk and complexity of each trial and not governed by one-size-fits-all requirements of sponsors and their contracted organisations. Overly burdening trials with too-rigorous requirements is pushing up costs and putting off investigators to undertake research.
- Trials in low-income settings need to contribute to clinical trial methodology research efforts.
Why Do We Need Trials and What Makes a Trial a Trial?
Clinical trials are needed globally to reduce disease burdens by helping developing safe and effective new therapies and vaccines. These solutions may be for non-communicable diseases like cancer and diabetes, or, as is especially needed in the poorest regions of the world, infectious disease. Developing countries are under-represented in research due to lack of commercial viability and trained researchers, yet it is in these poorest regions where research-led solutions could bring the greatest impact to high rates of early mortality.
As a research tool clinical trials are fundamental in the effort to develop new products by gaining the data required by regulators, whether for product license extensions for existing therapies for common ailments or to bring cutting edge new therapies and vaccines into approved use. However, there is also a need for clinical trials to bring evidence to determine how to improve the management of health issues; these studies often do not involve a medicinal product but instead compare different options, such as different types of management of an illness in hospital with community-based care. Or, for example, a clinical trial might be used to assess different mechanisms to improve patient adherence to therapy. These pragmatic disease management trials can bring about significant improvements in public health and often require large yet simple trial designs.
The World Health Organization and journal editors define clinical trials as “any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes” . Patients may be randomised to an intervention involving either an investigational new product or the standard-of-care treatment, or the patient might be randomised to be cared for by nurses who have been trained in one of two or more comparative ways.
Why Go Global?
Clinical trial data are often collected from varied populations to support a license application because geographically different trial sites are needed to ensure the product is safe and works in the same way in varying ethnic groups. This requirement is true whether it is a pharmaceutical company working on the next blockbuster drug or a non-for-profit partnership (which typically have a pharmaceutical partner involved in a non-for-profit capacity) developing a new drug or vaccine for a neglected disease. Here scientific and regulatory factors combine to encourage the globalisation of clinical trials.
Clinical trials are also being conducted across more diverse countries for economic reasons. Clinical trials are expensive and are taking longer to conduct than in the past, thus further compounding the increased costs , and this is the case for all types of trial, whether commercial or academic. There are many reasons for the increased cost and duration of clinical trials, but it is a widely held view that clinical regulations, or more precisely, the interpretation and implementation of these regulations, are a major factor . Few would argue with the importance of well-regulated clinical trials to ensure high ethical standards and that trial conduct and processes are producing valid and accurate data. However, there is a call for making trial regulation less complicated and more readily adaptable to risk, and for having guidelines that are globally applicable and adaptable to all types of trial ,. Such guidelines would be as easily applied to pragmatic trials of existing treatments or disease management questions as they would be for trials of new drugs and vaccines.
There are many justifiable reasons for running clinical trials across multiple countries and indeed continents, or even only in sites that are not in the sponsor's location. Some countries are able to recruit participants faster than others for varied and valid reasons. The trial could be for a rare health event, such as dengue fever or traumatic cerebral hemorrhage, and for these trials it is necessary to recruit many centers in diverse locations, each site perhaps recruiting just a few patients to avoid prolonging the duration of the trial and increasing the wait for lifesaving new interventions. It is also true that some regions of the globe are vastly more expensive than others to conduct trials. For example, a clinical trial in India can cost one-tenth of the price that it would cost in the US . Since clinical trials costs are largely driven by labour, much of these savings are from lower salaries to physicians, nurses, and trial coordinators. The time and cost of developing drugs or vaccine influences the final product cost and return on investment, so the logic of reducing trial costs is clear and reasonable.
What Are the Ethical, Scientific, and Operational Challenges of Running Trials across the Globe?
Clinical trials should be designed, conducted, and monitored in proportion to their relative risk and complexity . However, in developing countries it is our experience that external sponsors and their locally appointed contract research organisations (CROs) are often overly zealous in their interpretation of trial guidelines and apply a one-size-fits-all approach to trial coordination and monitoring, irrespective of the risk and complexity. This is often due to an inaccurate perception from the sponsor and/or CRO about the ability of the research sites to run high quality and compliant trials. This perspective can lead to overly cumbersome trials and to burdening of research sites with administrative requests and site visits that are not necessary. In addition, steps and processes are introduced that can alter the expectations of ethics committees, funders, and reviewers and become perpetuated, irrespective of the real need. Many research teams in developing countries do not have the experience to question the necessity of these overly stringent requirements, which therefore remain in place and become the expected norm for every clinical research study.
For example, some ethics committees insist on Data Safety and Monitoring Committees being put in place for every trial even if these committees are not needed or appropriate . However, trials groups often comply without challenging the request, and the requirement becomes a standard step in the process, without examining each time whether it is appropriate for the specific protocol in question. We are not suggesting in any way that processes and standards should be lower or different in developing countries, but we do feel that overly cautious application of regulations is common around the world- and that it creates a greater burden to research in resource-limited settings.
Table 1 provides examples of steps and issues in clinical trial conduct that could be adversely impacted by inappropriate interpretation of guidelines or overly keen CROs and sponsors. These steps are important for optimum trial conduct and should be carefully considered for each trial and its specific risks and complexity. However, overly “cooking” or implementing these steps can unnecessarily overburden and increase the cost of clinical trials, which results in slowing new product development and discourages investigators from conducting their own independent research.
In the US and the UK it is increasingly recognised that trials have become too expensive and bureaucratic, and initiatives such as the Clinical Trial Transformation Initiative  and the Medical Research Council's Methodology Research Hubs in the UK are trying to rationalise design, conduct, and regulation to improve clinical trial design and make running them easier, more attractive, and less expensive. There is a danger that developing and middle-income countries are not involved in this emerging enthusiasm and effort to make trial design more rational and attractive to potential researchers.
It is essential to protect participants in clinical trials from exploitation and this needs particular care and thought in developing countries where populations can be more vulnerable. To achieve this participant protection, great efforts have been made in recent years to strengthen ethical and regulatory review in developing countries, which is, of course, extremely necessary and important. However, whilst in high-income countries efforts have been made to streamline and simplify ethics and the regulatory review process, application to ethics committees has become highly administrative in resource-limited countries with increasing paper work, and multiple sequential reviews are often needed before a trial can start. This administrative hurdle unfortunately further discourages local academic researchers in developing countries . More wealthy foreign trial sponsors may well have the capacity to resource the administrative burden of getting protocols through these committees; however, low investment and support for ethics and regulatory committees in developing countries is a problem for external sponsors. When international product development efforts are delayed by slow review of trial protocols, this seriously increases the time it takes to develop new drugs and vaccines for diseases of poverty such as tuberculosis and malaria.
What Do We Need to Do Differently?
Clinical trials have gone global and this is certainly a good thing—on the whole. Conducting varying types of trials in low- and middle-income countries (LMICs) can be very positive and the experience research sites gain by working with commercial or not-for-profit sponsors raises research standards and brings health improvements to developing countries and badly needed investment to these research institutions. Externally sponsored trials also bring increasing capacity for research through training and engagement in product development and other global public health initiatives.
However, the global research community needs to improve efforts to support and encourage investigators from LMICs to seek to run their own trials. They need to be provided with incentives and a mandate (possibly from their ministries of health and employing institutions) to plan their own studies and opportunities to diversify beyond externally sponsored trials. A good example of a local investigator-led clinical trial is a recent study in Sri Lanka that addressed a locally relevant question—how to treat snakebites. Interestingly it was advice from a journal's statistician that helped the investigators demonstrate a life-saving intervention to prevent allergic reactions to anti-venom serum for snakebites, which is now being widely used . It is an example of a pragmatic trial that used existing therapies to solve a local issue. The fact that external statistical support was needed shows how capacity is limited and wide support and collaboration are important.
Widespread disparities in clinical care, scientific and health literacy, and economic and social development exist between developed and developing countries. These differences carry concerns about exploitation exacerbated by the power gap between patient-participants and physician-investigators. The vulnerability of developing world patient-participants has been discussed extensively in the past decade .
When running trials in vulnerable populations, such as rural communities in developing countries, detailed consideration needs to be given to engaging with the community, explaining the research that is planned, and then carefully selecting the most appropriate approaches for seeking fully informed consent . More social science-based research is needed to make sure that the best approaches, messages, and methods are being practiced in order to protect the study population (and wider community) and also to ensure that the message is being clearly explained and understood. Do those giving consent really understand what is being asked of them? Do they understand that they have a choice; that they are taking part in research and this differs from standard care and, most importantly, that they can say no?
Clinical trial methodology research is needed because there are great differences in cultures and perceptions across the globe, and what is appropriate in one place might not be in another, and so it might not be appropriate to simply export a requirement, and again for this requirement to become introduced unchecked into becoming a standard requirement. For example seeking assent from children is a legal requirement in many countries. Is it always appropriate to apply this rule everywhere? Should a child be asked for assent when they do not normally have any autonomy?
There is a need for training and support for clinical trial investigators and their teams, as well as a need for strengthening capacity for scientific and ethical review in these regions. This capacity needs to be cross-cutting and not focused on one disease or protocol if it is to leave trial sites with the skills and knowledge to run their own studies . New globally appropriate guidelines for good clinical practice would greatly benefit researchers working in non-investigational product trials irrespective of where they are in the world. These guidelines need to be informed by internationally based methodology research.
Risk and complexity-based assessment of trials would improve trial conduct, reduce costs, and enable key elements such as quality management to be more likely to pick up real issues that impact trial outcomes, rather than the one-size-fits-all approach to clinical trial monitoring (often described as “tick box checking”) .
We feel that pre-trial community engagement, ongoing dialogue, and post-trial information giving are important to build and foster community trust for clinical research. Researchers in the developing world should come from the same or similar community and relative standard of living in which the research is being done. Not only would mean they have a sense of belonging to that community and the country, but the country and the community also would own and take pride in their researchers. This relationship will only work if the community receives and perceives tangible and intangible benefits from research. Post-trial access to medicines and devices are an integral part of this creation of trust between researchers and the community. In the case of two clinical trials in Sri Lanka, for example, (one for a snakebite treatment and the other a treatment for yellow oleander poisoning ,), the products are not available locally because the costs are too high.
In addition we all need to be watchful about exporting mistakes made in the northern hemisphere. Whilst the US and Europe are examining how to encourage more academic trials and limit bureaucracy, these same problems are being applied with extra vigour in less experienced settings. We have found that when there is limited experience, those individuals tasked with reviewing research opt for caution and ask for more rather than less. Whilst this situation is correct and understandable, it highlights the need for research reviewers in developing countries to be better supported and provided with the knowledge and confidence to know which requirements to be applied and when. The current excess of caution is limiting research and making trials more expensive and complex than they need to be. The ramifications are important; too few academic trials and the slow development of new drugs and vaccines in regions of the world most burdened by disease directly impact efforts to reduce early mortality in diseases of poverty.
Finally, the globalisation of clinical trials should not be about running inexpensive trial sites to benefit distant people, but should focus on bringing research to populations who have previously been under-represented in clinical trials, and enabling these same communities the benefits resulting from new drugs, vaccines, and improvements in managing health.
Wrote the first draft of the manuscript: TAL SS. Contributed to the writing of the manuscript: TAL SS. ICMJE criteria for authorship read and met: TAL SS. Agree with manuscript results and conclusions: TAL SS.
- 1. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, et al. (2009) Clinical trial registration — looking back and moving ahead. N Engl J Med 356: 2734–2736.C. LaineR. HortonCD DeAngelisJM DrazenFA Frizelle2009Clinical trial registration — looking back and moving ahead.N Engl J Med35627342736
- 2. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D (2011) The cost of drug development: a systematic review. Health Policy 100: 4–17.S. MorganP. GrootendorstJ. LexchinC. CunninghamD. Greyson2011The cost of drug development: a systematic review.Health Policy100417
- 3. Yusuf S, Bosch J, Devereaux P (2008) Sensible guidelines for the conduct of large randomized trials. Clin Trials 5: 38–39.S. YusufJ. BoschP. Devereaux2008Sensible guidelines for the conduct of large randomized trials.Clin Trials53839
- 4. Lang T, Cheah PY, White NJ (2011) Clinical research: time for sensible global guidelines. Lancet 377: 1553–1555.T. LangPY CheahNJ White2011Clinical research: time for sensible global guidelines.Lancet37715531555
- 5. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, et al. (2009) Ethical and scientific implications of the globalization of clinical research. N Engl J Med 360: 816–823.SW GlickmanJG McHutchisonED PetersonCB CairnsRA Harrington2009Ethical and scientific implications of the globalization of clinical research.N Engl J Med360816823
- 6. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1996) Guideline for good clinical practice E6(R1). Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use1996Guideline for good clinical practice E6(R1)GenevaInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
- 7. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, et al. (2005) Issues in data monitoring and interim analysis of trials. Health Technol Assess 9: 1–238.AM GrantDG AltmanAB BabikerMK CampbellFJ Clemens2005Issues in data monitoring and interim analysis of trials.Health Technol Assess91238 iii–iv. iii–iv.
- 8. Grignolo A (2011) The Clinical Trials Transformation Initiative (CTTI). Annali dell'Istituto superiore di sanita 47: 14–18.A. Grignolo2011The Clinical Trials Transformation Initiative (CTTI).Annali dell'Istituto superiore di sanita471418
- 9. Ateudjieu J, Williams J, Hirtle M, Baume C, Ikingura J, et al. (2010) Training needs assessment in research ethics evaluation among research ethics committee members in three African countries: Cameroon, Mali and Tanzania. Dev World Bioeth 10: 88–98.J. AteudjieuJ. WilliamsM. HirtleC. BaumeJ. Ikingura2010Training needs assessment in research ethics evaluation among research ethics committee members in three African countries: Cameroon, Mali and Tanzania.Dev World Bioeth108898
- 10. de Silva HA, Pathmeswaran A, Ranasinha CD, Jayamanne S, Samarakoon SB, et al. (2011) Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS Med 8: e1000435.HA de SilvaA. PathmeswaranCD RanasinhaS. JayamanneSB Samarakoon2011Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial.PLoS Med8e1000435
- 11. Nundy S, Gulhati CM (2005) A new colonialism?–Conducting clinical trials in India. N Engl J Med 352: 1633–1636.S. NundyCM Gulhati2005A new colonialism?–Conducting clinical trials in India.N Engl J Med35216331636
- 12. Lang TA, Gould J, von Seidlein L, Lusingu JP, Mshamu S, et al. (2012) Approaching the community about screening children for a multicentre malaria vaccine trial. International Health 4: 47–54.TA LangJ. GouldL. von SeidleinJP LusinguS. Mshamu2012Approaching the community about screening children for a multicentre malaria vaccine trial.International Health44754
- 13. Lang TA, White NJ, Tran HT, Farrar JJ, Day NP, et al. (2010) Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis 4: e619.TA LangNJ WhiteHT TranJJ FarrarNP Day2010Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated.PLoS Negl Trop Dis4e619
- 14. Brosteanu O, Houben P, Ihrig K, Ohmann C, Paulus U, et al. (2009) Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials. Clin Trials 6: 585–596.O. BrosteanuP. HoubenK. IhrigC. OhmannU. Paulus2009Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.Clin Trials6585596
- 15. de Silva HJFM, Gunatilake SB, Kularatne SAM, Sellahewa KH (2002) Anti-venom for snakebite in Sri Lanka. Ceylon Medical Journal 47: 43–45.HJFM de SilvaSB GunatilakeSAM KularatneKH Sellahewa2002Anti-venom for snakebite in Sri Lanka.Ceylon Medical Journal474345
- 16. Juurlink DN, Sivilotti ML (2003) Multidose activated charcoal for yellow oleander poisoning. Lancet 362: 581; author reply 581.DN JuurlinkML Sivilotti2003Multidose activated charcoal for yellow oleander poisoning.Lancet362581; author reply 581